Company
Headquarters: Shanghai, China
Employees: 227
CEO: Dr. Kerry Levan Blanchard M.D., Ph.D.
HK$16.65 Billion
HKD as of Jan. 1, 2026
US$2.14 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. Everest Medicines Limited was founded in 2017 and is headquartered in Shanghai, China.
| Last Financial Reports Date | June 30, 2020 |
| Revenue TTM | HK$946.6 M |
| EBITDA | HK$-661,263,370 |
| Gross Profit TTM | HK$664.1 M |
| Profit Margin | -77.38% |
| Operating Margin | -62.04% |
| Quarterly Revenue Growth | 48.00% |
Everest Medicines Ltd has the following listings and related stock indices.
Stock: HKEX: 1952 wb_incandescent
Stock: FSX: 6HN wb_incandescent